DRKS00030164招募中不适用
Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study - C3G_EC
niversitätsklinikum Freiburg, Medizinische Klinik IV0 个研究点目标入组 14 人开始时间: 2022年9月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •Age>= 18 years, histopathological diagnosis of C3G.
排除标准
- •Age < 18 years
研究者
相似试验
已完成
1 期
Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney TransplantationComplications, Allograft KidneyNCT01327573Sanjay Kulkarni16
已完成
3 期
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia GravisRefractory Generalized Myasthenia GravisNCT02301624Alexion Pharmaceuticals, Inc.117
已完成
2 期
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion InjuryEnd-Stage Renal DiseaseKidney FailureGraft Reperfusion InjuryNCT01756508Russian Academy of Medical Sciences57
招募中
不适用
Prevalence and Pathological Features of C3 Dominant Glomerulonephritis Among Egyptian PopulationC3 NephropathyNCT06126471Sohag University100
终止
2 期
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal TransplantationAntibody-mediated RejectionHumoral RejectionNCT01895127Brigham and Women's Hospital11